Recent Finacing
Recent Raise
Forty Seven is a clinical-stage immuno-oncology company developing Hu5F9-G4, a humanized anti-CD47 monoclonal antibody that engages phagocytic pathways and is being evaluated in hematologic and solid tumors.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investors
See the team members at Forty Seven.
